Digestion and gut comfort is the main area connected here, and any felt benefit should be read together with the human evidence base.
Some human supplement-context evidence is present and directly informs the score.
Representative tier calculated from paper evidence that passed the collection audit.
The representative ingredient tier is calculated from these target-level evidence groups.
10 new papers were added in this period. No new risk signal was identified.
Standalone side-effect signals and combination cautions are listed separately.
No standalone side-effect or combination signal is currently clear enough to show from the collected papers. This does not mean there is no concern.
Paper IDs and full lists are private. Only study types and summaries are shown.
All the in vitro and in vivo evidence for the mechanism of action of glucosamine is examined as well as reviews the results of clinical trials and the published recommendations for the management of OA require revision.
CS+GH has comparable efficacy to celecoxib in reducing pain, stiffness, functional limitation and joint swelling/effusion after 6 months in patients with painful knee osteoarthritis, with a good safety profile.
Over 2 years, no treatment achieved a clinically important difference in WOMAC pain or function as compared with placebo, however, glucosamine and celecoxib showed beneficial but not significant trends.
Chs3p-dependent chitin synthesis in S. cerevisiae is regulated both by the levels of intermediates of the UDP-GlcNAc biosynthetic pathway and by an increase in the activity of the enzyme in the plasma membrane.
In patients with knee OA with at least moderate subjective improvement with prior glucosamine use, this study provides no evidence of symptomatic benefit from continued use of glucosamines sulfate.
The role of these compounds in the therapeutic arsenal for patients with knee OA is clarified with a small but significant reduction in the rate of joint space narrowing.